TY - JOUR
T1 - Safety assessment of the Cistanche tubulosa health food product Memoregain®
T2 - Genotoxicity and 28-day repeated dose toxicity test
AU - Liao, Po Lin
AU - Li, Ching Hao
AU - Tse, Ling Shan
AU - Kang, Jaw Jou
AU - Cheng, Yu Wen
N1 - Publisher Copyright:
© 2018 Elsevier Ltd
PY - 2018/8/1
Y1 - 2018/8/1
N2 - The pharmacological effects of Cistanches Herba, known as “Ginseng of the desert” have been extensively studied. In this study, we aimed to assess the genotoxic and oral toxic effects of the Cistanche tubulosa health food product Memoregain® using in vitro and in vivo tests. Ames tests using five strains of Salmonella typhimurium showed no signs of increased reverse mutation upon exposure to Memoregain® up to a concentration of 5 mg/plate. Exposure of Chinese hamster ovary (CHO-K1) cells to Memoregain® did not increase the frequency of chromosomal aberrations in vitro. Moreover, Memoregain® treatment did not affect the proportions of immature to total erythrocytes or the number of micronuclei in the immature erythrocytes of ICR mice. Additionally, after 28-day repeated oral dose toxicity tests (0, 0.15, 0.3, and 0.5g/kg body weight) in rats, no observable adverse effects were found. These toxicological assessments supported the safety of Memoregain® for human consumption.
AB - The pharmacological effects of Cistanches Herba, known as “Ginseng of the desert” have been extensively studied. In this study, we aimed to assess the genotoxic and oral toxic effects of the Cistanche tubulosa health food product Memoregain® using in vitro and in vivo tests. Ames tests using five strains of Salmonella typhimurium showed no signs of increased reverse mutation upon exposure to Memoregain® up to a concentration of 5 mg/plate. Exposure of Chinese hamster ovary (CHO-K1) cells to Memoregain® did not increase the frequency of chromosomal aberrations in vitro. Moreover, Memoregain® treatment did not affect the proportions of immature to total erythrocytes or the number of micronuclei in the immature erythrocytes of ICR mice. Additionally, after 28-day repeated oral dose toxicity tests (0, 0.15, 0.3, and 0.5g/kg body weight) in rats, no observable adverse effects were found. These toxicological assessments supported the safety of Memoregain® for human consumption.
KW - 28-day repeated oral dose toxicity
KW - Cistanche tubulosa
KW - Genotoxicity test
KW - No-observed-adverse-effect-level
KW - 28-day repeated oral dose toxicity
KW - Cistanche tubulosa
KW - Genotoxicity test
KW - No-observed-adverse-effect-level
UR - http://www.scopus.com/inward/record.url?scp=85048257949&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85048257949&partnerID=8YFLogxK
U2 - 10.1016/j.fct.2018.06.012
DO - 10.1016/j.fct.2018.06.012
M3 - Article
AN - SCOPUS:85048257949
SN - 0278-6915
VL - 118
SP - 581
EP - 588
JO - Food and Chemical Toxicology
JF - Food and Chemical Toxicology
ER -